Nuclear Receptors in the Etiology and Treatment of Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (1 December 2024) | Viewed by 1871

Special Issue Editors


E-Mail Website
Guest Editor
Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, 1 Drexel Dr, New Orleans, LA 70125, USA
Interests: effects of oncogenic kinase signaling on estrogen receptor signaling in breast cancer

E-Mail Website
Guest Editor
Division of Basic Sciences, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL 32307, USA
Interests: phytoestrogens and aromatase inhibitor resistance

Special Issue Information

Dear Colleagues,

Since the discovery of estrogen ablative therapy as a treatment model for breast cancer in the 19th century, targeting of nuclear receptors has been an effective strategy for the management of cancer.  However, these strategies are imperfect, as the same receptor signaling mechanisms that promote the deranged cellular functions in cancer are also responsible for the governance of physiological homeostasis in non-transformed tissues. In addition, de novo or acquired resistance to these therapies remains a significant clinical hurdle. Mechanisms ranging from posttranslational modification of receptors, cross-talk with oncogenic kinases, expression of alternative receptor isoforms, and development of point mutations are only a few of the mechanisms that have been suggested to contribute to the oncogenic potential of nuclear receptors, as well as to the therapeutic failure of nuclear receptor-targeting drugs.

Here, we seek to provide a platform for the dissemination of the latest findings around how nuclear receptor signaling impacts the progression of cancer, and how the understanding of these mechanisms might be exploited. We are pleased to invite you to submit your original article or review to this Special Issue of Cancers. We welcome your submissions on any topic relevant to nuclear receptors in cancer, including disease etiology, clinical pathology and prognosis, molecular mechanisms, drug targeting, endocrine disruption, and beyond.

We look forward to receiving your contribution.

Dr. Christopher C. Williams
Dr. Syreeta L. Tilghman
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • estrogen
  • progesterone androgen
  • testosterone
  • nuclear receptor
  • breast
  • ovarian
  • prostate
  • uterine
  • cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

4 pages, 182 KiB  
Editorial
Androgen Receptor Signaling in Prostate Cancer Genomic Subtypes
by Mohamed Ali Hussein and Gnanasekar Munirathinam
Cancers 2023, 15(20), 4969; https://doi.org/10.3390/cancers15204969 - 13 Oct 2023
Cited by 2 | Viewed by 1367
Abstract
Prostate cancer (PCa) constitutes a significant cause of mortality, with over 37,000 new deaths each year [...] Full article
(This article belongs to the Special Issue Nuclear Receptors in the Etiology and Treatment of Cancer)
Back to TopTop